NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference

Rhea-AI Summary

NexImmune, Inc. (Nasdaq: NEXI) announced that Scott Carmer, CEO, will present at the virtual 2021 Human Health Innovation Conference on June 22, 2021, at 9:20 a.m. ET. The presentation will be available via live webcast and later as a replay on NexImmune's website. The company, focused on innovative immunotherapy, utilizes its proprietary AIM™ nanoparticle technology to generate targeted immune responses with decreased off-target effects. Its lead programs, NEXI-001 and NEXI-002, are in clinical trials for relapsed AML post-stem cell transplant and refractory multiple myeloma.

GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Human Health Innovation Conference on Tuesday, June 22, 2021 at 9:20 a.m. Eastern time.

The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations. A replay will be available on the NexImmune website following the presentation.

About NexImmune

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

For more information, visit www.neximmune.com.

Contacts

Investors:
Chad Rubin, SVP Corporate Affairs
NexImmune, Inc.
646.319.3261
crubin@neximmune.com

FAQ

When is NexImmune presenting at the 2021 Human Health Innovation Conference?

NexImmune will present on June 22, 2021, at 9:20 a.m. Eastern time.

Where can I watch NexImmune's conference presentation?

The presentation will be accessible via live webcast on NexImmune's investor website.

What is the AIM technology used by NexImmune?

AIM™ is a proprietary nanoparticle technology that directs T cell-mediated immune responses.

What clinical trials are NexImmune's lead programs involved in?

NEXI-001 is in trials for relapsed AML after stem cell transplantation, while NEXI-002 targets refractory multiple myeloma.

How does NexImmune's technology reduce off-target toxicities?

NexImmune’s AIM technology engages and activates T cells specifically, aiming for precision and durability in immune responses.